This document in English is a translation of the original in Swedish. In case of any discrepancy, the Swedish original will prevail. Increased turnover. Positive EBITDA. January - June 2025 Turnover totalled 14 848 (12 230) TSEKProfit after financial items -1 141 (-4 960) TSEK Earnings per share -0,0 (-0,1) SEK April - June 2025 Turnover totalled 7 471 (6 236) TSEKProfit after financial items -587 (-2 017) TSEK Earnings per share -0,0 (-0,0) SEK The second quarter of 2025 marks another positive step forwar ...

Core Points - Bang & Olufsen has announced a share buyback programme with a total value of up to DKK 65 million, set to begin immediately and conclude by 14 August 2026 [1] - The programme aims to hedge share-based long-term incentive programmes approved by the general meeting [1] - The share buyback is compliant with EU regulations, specifically the EU Commission Regulation No. 596/2014 and the Safe Harbour Regulation [2] Summary by Sections - **Programme Details** - The share buyback programme is authorized by the board of directors, allowing the acquisition of treasury shares up to 10% of the company's share capital [3] - As of the initiation, Bang & Olufsen holds 3,113,183 own shares, which is 2.1% of the total share capital [4] - **Management and Execution** - Nordea has been appointed as the lead manager for the share buyback programme, making independent trading decisions [4] - The maximum number of shares to be acquired is limited to 5,000,000, and purchases will not exceed 10% of the company's share capital at any time [7] - **Trading Guidelines** - Shares will be purchased at prices not exceeding the higher of the last independent transaction price or the highest independent purchase bid [7] - Daily purchases are capped at 25% of the average daily trading volume over the preceding 20 trading days [7] - The company will report purchases made under the programme at least every seventh trading day [7] - The programme can be suspended or stopped at any time with a company announcement [7]

Core Viewpoint - Schouw & Co. reported a stable yet challenging second quarter of 2025, with performance in line with expectations despite global market changes [3][4]. Financial Performance - Consolidated revenue for Q2 2025 was DKK 8.5 billion, reflecting a 2% decrease compared to Q2 2024 [7]. - EBITDA for the same period was DKK 706 million, down 4% year-over-year [7]. - Operational cash flow improved significantly to DKK 542 million, marking a 61% increase [7]. - Earnings per share decreased by 3% to DKK 10.18 [7]. - Return on invested capital (ROIC) excluding goodwill was 12.5%, a decrease of 1.3 percentage points [7]. Portfolio Performance - BioMar, GPV, and HydraSpecma demonstrated strong resilience, while Borg Automotive faced challenging market conditions [4]. - The diversified portfolio helped maintain stability amid global economic fluctuations, particularly in the Chinese export markets [3]. Future Outlook - The company has narrowed its full-year 2025 revenue and EBITDA guidance within the previously announced range [4]. - Schouw & Co. is exploring a potential separate listing of BioMar, with preparatory work ongoing and a banking syndicate established for this purpose [5]. If deemed value-creating, the listing could occur in the first half of 2026 [5].

Core Viewpoint - BioPorto A/S reported continued progress in executing its strategic objectives, highlighted by strong sales growth in NGAL products and the initiation of its commercial journey in the US market with the first order of ProNephro AKI [1][3][4]. Financial Performance - Total revenue for the second quarter of 2025 reached DKK 10.6 million, a 15% increase compared to DKK 9.2 million in the same period last year [7]. - For the first half of 2025, total revenue was DKK 18.3 million, reflecting a 2% decrease from DKK 18.7 million in the first half of 2024, primarily due to lower antibody sales [5][9]. - NGAL sales increased by 39% in Q2 2025 compared to Q2 2024, with a 23% rise in the US and a 71% increase in the rest of the world [6][7]. - Adjusted EBITDA loss for Q2 2025 was DKK 18.4 million, compared to DKK 16.2 million in Q2 2024, driven by higher costs associated with clinical studies [7][9]. - The adjusted EBITDA loss for the first half of 2025 was DKK 46.5 million, up from DKK 31.5 million in the same period last year [5][9]. Strategic Developments - A significant milestone was achieved with the receipt of the first purchase order for ProNephro AKI (NGAL) for the US market, marking the start of its commercial launch [6]. - The company is progressing towards FDA submission for ProNephro AKI by the end of 2026, with patient enrollment in clinical studies on track [4][6]. - The board was restructured, with Jens Due Olsen appointed as Chairman and Carsten Buhl as the new CEO effective September 1, 2025, to lead the next growth phase [6]. Guidance - The company has narrowed its full-year revenue guidance for 2025 to DKK 45-50 million, down from the previous range of DKK 45-60 million [8][14]. - Adjusted EBITDA loss guidance for 2025 is now expected to be between DKK 75-80 million, previously estimated at DKK 75-85 million [14].

Group 1 - Sampo plc has initiated a share buyback program with a maximum value of EUR 200 million, starting from 7 August 2025 [1][2] - On 14 August 2025, Sampo plc acquired a total of 327,395 A shares at an average price of EUR 9.85 per share [1] - Following the transactions, Sampo plc now holds a total of 1,974,201 A shares, which represents 0.07% of the total shares outstanding [2] Group 2 - The share buyback program is in compliance with the Market Abuse Regulation (EU) 596/2014 and the Commission Delegated Regulation (EU) 2016/1052 [1] - The authorization for the buyback program was granted during Sampo's Annual General Meeting on 23 April 2025 [1]

Financial Performance - In Q2 2025, Pandora reported revenue of DKK 7,075 million, up from DKK 6,771 million in Q2 2024, reflecting an organic growth of 8% compared to 15% in the same quarter last year [4][5] - The gross margin for Q2 2025 was 79.3%, despite a 170 basis points headwind from foreign exchange, commodities, and tariffs, down from 80.2% in Q2 2024 [5] - The EBIT margin for Q2 2025 was 18.2%, a decline of 160 basis points year-over-year, with a constant currency EBIT margin of 19.4% [5][6] - Reported EPS growth in Q2 2025 was 6%, or 18% in constant currency [5] Market and Growth Insights - Like-for-like (LFL) growth was 3% in Q2 2025, with the US showing strong LFL growth of 8% and the Rest of Pandora at 6% [5] - LFL growth in Europe was 1%, driven by double-digit growth in countries like Spain, Portugal, the Netherlands, and Poland [5] - The company maintains its guidance for 2025, projecting organic growth of 7-8% and an EBIT margin of around 24%, despite current macroeconomic uncertainties [5] Strategic Initiatives - Pandora is focusing on becoming a full jewellery brand by investing in four strategic pillars: brand, design, markets, and personalization [5] - Key initiatives for H2 2025 include launching two new collections, Pandora Talisman and Minis, aimed at refreshing the core charms and carriers offering [5] - The company is preparing a new chapter of the "BE LOVE" marketing campaign, emphasizing emotional storytelling and local talent engagement [5] Current Trading and Outlook - Current trading in July has seen LFL growth at around 2%, impacted by a weak End of Season Sale and the timing of product launches [5] - Despite challenges, Pandora remains on track to achieve an EBIT margin of around 25% by 2026, excluding tariffs, with current tariff levels adding a 120 basis points headwind [5]

Core Viewpoint - UnionPay's Poetry POS Machine initiative successfully showcased the poems of Chinese children at a lantern festival in Thailand, promoting cultural exchange and supporting local education through donations [1][4]. Group 1: Event Highlights - The "Poetry Lights the Heart's Lantern" festival featured a prominent UnionPay charity booth under a friendship lantern display, showcasing children's poems in Chinese and Thai [2]. - Thai children participated by reciting poems from their Chinese peers, enhancing cultural appreciation and joy [3]. - Visitors could donate via UnionPay cards, receiving bilingual poetry receipts or recording poetry readings for unique postcards [3]. Group 2: Charitable Impact - All donations from the event will be directed to a local Thai charity foundation aimed at improving the lives and education of local children [4]. - The Poetry POS Machine initiative, launched in 2019, has reached over 400 schools in mountainous regions of China, benefiting more than 7,000 children through art education programs [6]. Group 3: UnionPay's Global Presence - UnionPay is a leading international card network, accepted in 183 countries and regions, emphasizing its commitment to cultural exchange despite geographical distances [5]. - The initiative has collected over 6,000 poems and established public welfare libraries and book corners in Jinzhai County, Anhui Province [7].

Company Overview - Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company focused on developing and commercializing innovative medicines for rare neuromuscular diseases with high unmet medical needs [2] - The company holds an exclusive license for AGAMREE® (vamorolone), a dissociative steroid, for all indications worldwide from ReveraGen [2] - AGAMREE is approved for the treatment of Duchenne muscular dystrophy (DMD) in multiple regions, including the U.S., EU, UK, China, and Hong Kong [2] Recent Developments - Santhera Pharmaceuticals and Highbridge Capital Management have mutually agreed to extend the maturity date of an existing CHF 7 million private convertible bond to 30 September 2025 [1]

Core Insights - KH Group's net sales from continuing operations increased by 4% year-on-year to EUR 95.9 million for the first half of 2025, while operating profit decreased [6][10] - The profitability of KH-Koneet declined despite a 9% increase in net sales, indicating challenges in maintaining margins [6][10] - The Nordic Rescue Group experienced a decline in net sales, but its operating profit remained stable compared to the previous period [3][10] Financial Performance - For the second quarter of 2025, net sales were EUR 54.2 million, up from EUR 52.2 million in the same period last year, with a comparable operating profit of EUR 0.8 million, down from EUR 2.4 million [8][9] - The first half of 2025 saw comparable operating profit at EUR 1.0 million, a decrease from EUR 2.3 million in the previous year [10] - The Group's equity per share decreased to EUR 0.83 from EUR 1.25, with a return on equity for the rolling 12 months at -40.8% [6] Strategic Developments - KH Group is in the process of divesting its Indoor Group business, with a financial advisor engaged to explore options, aiming for completion in 2025 [4][12] - A reform program in Indoor Group is expected to improve operating profit by at least EUR 10 million annually by the end of 2026, with significant savings already realized in 2025 [5][12] - The company aims to focus on the growth of its core business, KH-Koneet, while assessing exit opportunities for other business areas [12][13] Future Outlook - The guidance for 2025 estimates that net sales will remain around EUR 194.0 million, with comparable operating profit expected to be approximately EUR 7.2 million, maintaining levels from the previous year [13][14] - The company plans to invest in core business growth and pay dividends after significant exits, adhering to its balance sheet structure and financing agreements [12][13]

Core Points - Propanc Biopharma, Inc. is set to begin trading on Nasdaq under the symbol PPCB after pricing an underwritten public offering of 1,000,000 shares at $4.00 per share, expected to yield approximately $4 million in gross proceeds [1][2] - The offering is anticipated to close on August 18, 2025, and includes a 45-day option for the underwriter to purchase an additional 150,000 shares [2][3] - The company’s shares were previously quoted on the OTC Markets, Pink Tier, and will cease to be quoted as of August 14, 2025, with no action required from stockholders [3] Company Overview - Propanc Biopharma, Inc. is focused on developing novel cancer treatments aimed at preventing recurrence and metastasis of solid tumors, specifically targeting pancreatic, ovarian, and colorectal cancers [6][7] - The company’s therapy utilizes pancreatic proenzymes to target and eradicate cancer stem cells, leveraging the body's natural defense mechanisms against cancer [6][7]